Alzheimer’s Disease: Is It Time to Rethink the Brain’s Immune System?
Table of Contents
Alzheimer’s disease, a devastating neurological condition affecting over 50 million people globally, may not be a primary disease of the brain, but rather a disorder of the brain’s immune system, according to groundbreaking new research. Years of focusing on the buildup of beta-amyloid plaques may have led scientists down a fruitless path, and a shift in perspective could unlock the key to effective treatments.
Recent years have witnessed increasing controversy in the pursuit of an Alzheimer’s cure. In July 2022, Science magazine reported concerns over potentially fabricated data in a 2006 Nature paper that initially linked beta-amyloid to the disease’s development. This revelation followed the contentious 2021 approval of aducanumab by the US Food and Drug Administration, a beta-amyloid targeting antibody approved despite incomplete and contradictory data. The debate surrounding aducanumab highlights the urgent need for a more robust understanding of the disease.
Escaping the Beta-Amyloid Rut
For decades, the dominant theory surrounding Alzheimer’s has centered on preventing the formation of beta-amyloid clumps. Scientists have largely focused on this approach, often overlooking alternative explanations. Unfortunately, this dedication to studying abnormal protein clumps has yet to yield a successful drug or therapy. A new way of thinking about Alzheimer’s is now a top priority in brain science.
Researchers at the Krembil Brain Institute at the University Health Network in Toronto are pioneering a new theory. Based on 30 years of research, they propose that Alzheimer’s is fundamentally a disorder of the brain’s immune system.
The immune system, present in every organ, works to repair injuries and defend against foreign invaders. When the body experiences trauma or infection, the immune system springs into action. These same processes occur within the brain, initiating repair after injury and fighting off bacterial infections.
Alzheimer’s as an Autoimmune Disease
This research suggests that beta-amyloid isn’t an abnormally produced protein, but a naturally occurring molecule integral to the brain’s immune response. It’s supposed to be there, playing a key role when the brain experiences trauma or infection. The problem arises from a critical misidentification.
Due to striking similarities between the fat molecules in bacterial membranes and those in brain cells, beta-amyloid struggles to differentiate between friend and foe. It mistakenly attacks healthy brain cells, leading to chronic, progressive brain cell dysfunction and ultimately, dementia. This misdirected attack positions Alzheimer’s as an autoimmune disease, where the body’s defense system turns against itself.
While autoimmune diseases like rheumatoid arthritis are often treated with steroid-based therapies, these approaches are unlikely to be effective against Alzheimer’s. The brain’s unique complexity demands a different strategy. In this new model, beta-amyloid is not the enemy, but a misguided protector. Targeting other immune-regulating pathways within the brain, researchers believe, will pave the way for effective treatments.
Beyond Beta-Amyloid: Emerging Theories
The autoimmune theory is just one of several emerging perspectives on Alzheimer’s. Some scientists are investigating the role of mitochondria, the energy factories within brain cells, believing that dysfunction in these structures contributes to the disease. Others propose that a specific brain infection, potentially originating from oral bacteria, could be a key factor. Still others are exploring the possibility of abnormal metal handling – specifically zinc, copper, or iron – within the brain.
It is gratifying to see new thinking about this age-old disease. A new diagnosis is made every three seconds, and the impact on individuals and families is profound. Often, people living with Alzheimer’s disease are unable to recognize even their closest loved ones.
Alzheimer’s represents a significant public health crisis, demanding innovative ideas and fresh approaches. For the well-being of those affected and to alleviate the strain on healthcare systems, a deeper understanding of Alzheimer’s – its causes, and potential treatments – is urgently needed.
Donald Weaver, Professor of Chemistry and Director of Krembil Research Institute, University Health Network, University of Toronto.
This article is republished from The Conversation under a Creative Commons license. Read the original article. An earlier version of this article was published in September 2022.
- Latest Advances in Alzheimer’s Disease Treatment and Diagnosis (news-usa.today)
